Literature DB >> 32556873

Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA.

Danielle R Fine1,2, David Herzberg3, Sarah E Wakeman4,5.   

Abstract

History has demonstrated cyclical trends in opioid use in the USA, alternating between high rates of prescribing driven by compassion and marketing and restrictive prescribing driven by stigma and fear of precipitating addiction and other harms. Two under-recognized yet powerful forces driving these trends are societal biases against individuals who use and are addicted to drugs, as well as a recognized social determinant of health, institutional discrimination. In the context of these influential forces, which are often based on racist and classist ideologies, we examine the history of opioid use in the USA from the 1800s when the vast majority of those addicted to opioids were middle- to upper-class women to the present-day white-washed narrative of the opioid crisis. As the demographics of those affected by opioid use and addiction has started to shift from white communities to communities of color, we cannot allow the preliminary success observed in white communities to obscure rising mortality rates from opioids in black and Latinx communities. To do so, we highlight ways to prevent racist and classist ideologies from further shaping responses towards opioid use. It is important to acknowledge the long history that has influenced responses to opioid use in the USA and take active steps towards promoting a sense of compassion towards all individuals who use and those who are addicted to drugs.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32556873      PMCID: PMC7947135          DOI: 10.1007/s11606-020-05974-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  22 in total

1.  Is the Prescription Opioid Epidemic a White Problem?

Authors:  Helena Hansen; Julie Netherland
Journal:  Am J Public Health       Date:  2016-12       Impact factor: 9.308

2.  Entitled to Addiction?: Pharmaceuticals, Race, and America's First Drug War.

Authors:  David Herzberg
Journal:  Bull Hist Med       Date:  2017       Impact factor: 1.314

3.  White opioids: Pharmaceutical race and the war on drugs that wasn't.

Authors:  Julie Netherland; Helena Hansen
Journal:  Biosocieties       Date:  2017-06-28

4.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

5.  Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients.

Authors:  Julie R Gaither; Kirsha Gordon; Stephen Crystal; E Jennifer Edelman; Robert D Kerns; Amy C Justice; David A Fiellin; William C Becker
Journal:  Drug Alcohol Depend       Date:  2018-08-06       Impact factor: 4.492

6.  Powder cocaine and crack use in the United States: an examination of risk for arrest and socioeconomic disparities in use.

Authors:  Joseph J Palamar; Shelby Davies; Danielle C Ompad; Charles M Cleland; Michael Weitzman
Journal:  Drug Alcohol Depend       Date:  2015-02-02       Impact factor: 4.492

7.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

Authors:  Art Van Zee
Journal:  Am J Public Health       Date:  2008-09-17       Impact factor: 9.308

8.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

9.  OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.

Authors: 
Journal:  J Pain Palliat Care Pharmacother       Date:  2004

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018.

Authors:  Nana Wilson; Mbabazi Kariisa; Puja Seth; Herschel Smith; Nicole L Davis
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-20       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.